Vorinostat Clinical Trials (2026): 272 Studies for Lymphoma & Multiple Myeloma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
272 Vorinostat clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 178 indications (including Lymphoma & Multiple Myeloma) and 17,692 total planned enrollment. 6 Phase 3 Vorinostat trials and 86 Phase 2 are listed. 12 Vorinostat clinical trials are actively recruiting at 41 U.S. sites across 23 states. Most recent activity: NCT02559778 (Sep 2035).
Where to Participate: All Vorinostat Trial Sites in the U.S. (41 sites across 23 states)
Every actively recruiting Vorinostattrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama/Children's of Alabama | Birmingham35233 | NCT02559778 | Map |
| AZ | Phoenix Children's Hospital | Phoenix85016 | NCT05848687 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202 | NCT05848687 | Map |
| AR | Arkansas Children's Hospital | Little Rock72202 | NCT02559778 | Map |
| CA | Children's Hospital Los Angeles | Los Angeles90027 | NCT05848687 | Map |
| CA | Valley Children's Hospital | Madera93636 | NCT05848687 | Map |
| CA | UCSF Benioff Children's Hospital Oakland | Oakland94609 | NCT02559778 | Map |
| CA | Children's Hospital of Orange County | Orange92868 | NCT05848687 | Map |
| CA | Stanford University | Palo Alto94304 | NCT05848687 | Map |
| CA | Rady Children's Hospital | San Diego92123 | NCT02559778 | Map |
| CT | Connecticut Children's Hospital | Hartford06106 | NCT02559778 | Map |
| FL | Nicklaus Children's Miami | Miami33155 | NCT02559778 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT05848687 | Map |
| FL | Arnold Palmer Hospital for Children | Orlando32806 | NCT02559778 | Map |
| FL | St. Joseph's Children's Hospital | Tampa33614 | NCT02559778 | Map |
| GA | Augusta University Health | Augusta30912 | NCT02559778 | Map |
| HI | Kapiolani Medical Center for Women and Children | Honolulu96813 | NCT02559778 | Map |
| KY | Norton Children's Research Institute/Affiliated with University of Louisville School of Medicine | Louisville40202 | NCT02559778 | Map |
| MD | National Institutes of Health Clinical Center | Bethesda20892 | NCT03167437 | Map |
| MI | Helen DeVos Children's Hospital | Grand Rapids49503 | NCT02559778 | Map |
| MN | Children's Hospital and Clinics of Minnesota | Minneapolis55404 | NCT02559778 | Map |
| MN | Children's Hospital of Minnesota | Minneapolis55404 | NCT05848687 | Map |
| MN | University of Minnesota | Minneapolis55414 | NCT06693284 | Map |
| MO | Cardinal Glennon Children's Medical Center | St Louis63104 | NCT02559778 | Map |
| NY | Memorial Sloan Kettering Cancer Center | New York10065 | NCT05848687 | Map |
| NY | New York Medical College | Valhalla10595 | NCT04308330 | Map |
| NC | University of North Carolina | Chapel Hill27514 | NCT07217379 | Map |
| NC | Levine Children's Hospital | Charlotte28204 | NCT02559778 | Map |
| OR | Doernbecher Children's Hospital | Portland97239 | NCT05848687 | Map |
| OR | Randall Children's Hospital | Portland97227 | NCT02559778 | Map |
| PA | Penn State Milton S Hershey Medical Center | Hershey17033-0850 | NCT05848687 | Map |
| PA | Penn State Milton S. Hershey Medical Center and Children's Hospital | Hershey17033 | NCT02559778 | Map |
| SC | Medical University of South Carolina | Charleston29425 | NCT02559778 | Map |
| TX | Dell Children's Blood and Cancer Center | Austin78723 | NCT02559778 | Map |
| TX | Children's Medical Center | Dallas75235 | NCT02559778 | Map |
| TX | MD Anderson | Houston77030 | NCT05848687 | Map |
| TX | University of Texas Health Science Center San Antonio | San Antonio78229 | NCT05848687 | Map |
| UT | University of Utah Huntsman Cancer Institute | Salt Lake City84108 | NCT05848687 | Map |
| VA | Children's Hospital of The King's Daughters | Norfolk23507 | NCT05848687 | Map |
| WA | Fred Hutch/University of Washington Cancer Consortium | Seattle98109 | NCT06145633 | Map |
| WI | Children's Wisconsin | Milwaukee53226 | NCT05317403 | Map |
Vorinostat clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | completed | terminated | withdrawn | not yet recruiting | unknown | no longer available | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 2 | 3 | ||||||
| P1 | 5 | 7 | 77 | 16 | 2 | 1 | 108 | ||
| P1/P2 | 2 | 6 | 29 | 20 | 1 | 1 | 59 | ||
| P2 | 2 | 3 | 44 | 23 | 7 | 2 | 5 | 86 | |
| P2/P3 | 1 | 1 | 1 | 3 | |||||
| P3 | 4 | 1 | 1 | 6 | |||||
| N/A | 4 | 1 | 2 | 7 |
Recruiting Vorinostat clinical trials (12)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT02559778 | PEDS-PLANPediatric Precision Laboratory Advanced Neuroblastoma Therapy | P2 | Neuroblastoma | 500 | Sep 2015 |
| NCT03167437 | An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab | P1/P2 | Crohn's Disease | 35 | Oct 2017 |
| NCT05848687 | TINI 2TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | P1/P2 | Lymphoblastic Leukemia | 90 | Nov 2023 |
| NCT07261241 | NANT 2021-02NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | P2 | Neuroblastoma | 118 | Jul 2026 |
| NCT06995521 | GVHDVorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population | P2 | GVHD | 55 | May 2026 |
| NCT04308330 | NYMC195Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | P1 | Ewing Sarcoma | 30 | Mar 2017 |
| NCT06145633 | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | P2 | Castration-Resistant Prostate Carcinoma | 15 | Sep 2024 |
| NCT07150026 | An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome | P1 | Pitt Hopkins Syndrome | 5 | Mar 2026 |
| NCT07150013 | Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome | P1 | Rett Syndrome | 15 | Mar 2026 |
| NCT07217379 | DELIVER-02The DART DELIVER-02 Study | P1 | HIV (Human Immunodeficiency Virus) | 24 | Oct 2025 |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | P1 | Acute Myeloid Leukemia, in Relapse | 40 | Mar 2023 |
| NCT06693284 | A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] | Early P1 | Primary Malignant Peripheral Nerve Sheath Tumors | 8 | Nov 2025 |
Vorinostat clinical trials by indication
Lymphoma (15)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02589145 | — | P1/P2 | terminated | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype |
| NCT00875056 | MK-0683 | P2 | completed | Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) |
| NCT00720876 | — | P2 | completed | Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma |
| NCT01120834 | DLBCL | P1/P2 | completed | Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) |
| NCT01421173 | SCT | P1 | completed | Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies |
| NCT01276717 | — | P1 | completed | Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma |
| NCT01169532 | — | P1 | completed | Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma |
| NCT00561418 | — | P1 | completed | Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma |
| + 7 more, see All trials below. | ||||
Multiple Myeloma (13)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01297764 | QUAD | P1/P2 | active not recruiting | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma |
| NCT01554852 | Myeloma XI | P3 | unknown | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients |
| NCT01038388 | — | P1 | completed | A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma |
| NCT00729118 | — | P1 | completed | Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma |
| NCT01720875 | MUKfour | P2 | completed | Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) |
| NCT00857324 | — | P1/P2 | terminated | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients |
| NCT01492881 | — | P2 | withdrawn | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma |
| NCT01502085 | RZD | P1/P2 | completed | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens |
| + 5 more, see All trials below. | ||||
Breast Cancer (9)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00616967 | — | P2 | active not recruiting | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer |
| NCT00788112 | — | P1 | completed | Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast |
| NCT00416130 | — | P1/P2 | unknown | Clinical Trial of SAHA in Patients With Breast Cancer |
| NCT00574587 | — | P1/P2 | completed | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy |
| NCT00262834 | — | P2 | completed | Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer |
| NCT01118975 | GCC 0845 | P1/P2 | terminated | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers |
| NCT00365599 | — | P2 | completed | Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer |
| NCT00258349 | — | P1/P2 | completed | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer |
| + 1 more, see All trials below. | ||||
Neuroblastoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02559778 | PEDS-PLAN | P2 | recruiting | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy |
| NCT07261241 | NANT 2021-02 | P2 | not yet recruiting | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab |
| NCT03561259 | OPTIMUM | P2 | unknown | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects |
| NCT03332667 | — | P1 | completed | MIBG With Dinutuximab +/- Vorinostat |
| NCT02035137 | N2011-01 | P2 | completed | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat |
| NCT01019850 | N2007-03 | P1 | completed | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma |
| NCT01838187 | — | N/A | no longer available | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma |
Unspecified Adult Solid Tumor, Protocol Specific (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00331955 | — | P1 | completed | Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors |
| NCT00324480 | — | P1 | completed | Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors |
| NCT00243100 | — | P1 | completed | Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors |
| NCT00121277 | — | P1 | completed | Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors |
| NCT00287937 | — | P1 | completed | Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors |
| NCT00227513 | — | P1 | completed | Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors |
Male Breast Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01720602 | — | N/A | completed | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy |
| NCT01084057 | — | P1 | completed | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer |
| NCT01153672 | — | N/A | completed | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy |
| NCT00368875 | — | P1/P2 | completed | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer |
| NCT00132002 | — | P2 | terminated | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer |
Leukemia (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00948064 | AML | P2 | completed | Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| NCT00882206 | — | P2 | terminated | Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia |
| NCT00818649 | — | P2 | terminated | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia |
| NCT00816283 | — | P1 | completed | Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia |
| NCT00005634 | — | P1 | completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy |
Acute Myeloid Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03843528 | — | P1 | active not recruiting | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation |
| NCT01802333 | — | P3 | completed | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia |
| NCT01534260 | — | P1/P2 | completed | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype |
| NCT01039363 | — | P2 | unknown | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia |
HIV-1 Infection (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03212989 | XTRA | P1 | completed | Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART) |
| NCT03803605 | — | P1 | completed | Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons |
| NCT02707900 | VORVAX | P1 | terminated | Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection |
| NCT01319383 | — | P1/P2 | completed | The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART |
Acute Lymphoblastic Leukemia (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02553460 | ALL | P1/P2 | active not recruiting | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I |
| NCT03117751 | — | P2/P3 | active not recruiting | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma |
| NCT01483690 | — | P1/P2 | terminated | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL |
| NCT01312818 | ALL | P2 | terminated | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) |
Advanced Cancers (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01266057 | — | P1 | completed | Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer |
| NCT02042989 | — | P1 | completed | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies |
| NCT01983969 | — | P1/P2 | completed | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma |
| NCT01608139 | — | P1 | withdrawn | Study of Curcumin, Vorinostat, and Sorafenib |
Advanced Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01087554 | — | P1 | active not recruiting | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer |
| NCT01339871 | — | P1 | completed | Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies |
| NCT00907738 | MK-0683 | P2 | completed | A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) |
| NCT00106626 | — | P1 | completed | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors |
Malignant Solid Tumour (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01023737 | — | P1 | completed | Hydroxychloroquine + Vorinostat in Advanced Solid Tumors |
| NCT00635791 | — | P1 | completed | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer |
| NCT00801151 | — | P1 | terminated | Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer |
Pancreatic Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00948688 | — | P1/P2 | terminated | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas |
| NCT00983268 | — | P1 | completed | Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer |
| NCT00831493 | — | P1/P2 | terminated | Vorinostat Plus Radiation Therapy in Pancreatic Cancer |
Adult Giant Cell Glioblastoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00731731 | — | P1/P2 | completed | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme |
| NCT00641706 | — | P2 | completed | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme |
| NCT00238303 | — | P2 | completed | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme |
HIV Infections (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03382834 | — | P2 | completed | Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors |
| NCT03198559 | — | P1/P2 | terminated | Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART |
Glioblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03426891 | — | P1 | completed | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma |
| NCT00762255 | — | P1 | completed | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma |
Non-Small-Cell Lung Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02151721 | VICTORY-J | P1 | unknown | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer |
| NCT00565227 | — | P1 | terminated | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. |
Accelerated Phase Chronic Myelogenous Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01789255 | — | P2 | completed | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies |
| NCT00357305 | — | P1 | completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
Myelodysplastic Syndrome (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01593670 | — | P2 | completed | Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes |
| NCT01748240 | GFM-AZA-VOR | P2 | terminated | Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure |
Leukemia, Myeloid, Acute (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01617226 | RAvVA | P2 | completed | Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS |
| NCT00875745 | AML | P1 | completed | Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) |
Adult Anaplastic Astrocytoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00268385 | — | P1 | active not recruiting | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas |
| NCT01378481 | — | P1 | terminated | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma |
Brain Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00946673 | SRS | P1 | completed | Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer |
| NCT01110876 | GBM | P1/P2 | terminated | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) |
Adult Nasal Type Extranodal NK/T-cell Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01116154 | — | P1 | terminated | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma |
| NCT00601718 | — | P1/P2 | completed | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
Ovarian Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00910000 | — | P1/P2 | terminated | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer |
| NCT00772798 | — | P2 | unknown | A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer |
Adult Acute Megakaryoblastic Leukemia (M7) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00895934 | — | P1/P2 | completed | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML |
| NCT00673153 | — | P2 | terminated | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia |
Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00702962 | — | P1/P2 | terminated | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer |
| NCT00697476 | — | P1/P2 | terminated | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC |
Relapsed or Refractory Multiple Myeloma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00642954 | MM | P1 | completed | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) |
| NCT00773838 | MK0683 | P2 | completed | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) |
Hodgkin's Disease (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00667615 | DLBCL | P1/P2 | completed | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) |
| NCT00691210 | SAHA | P1 | completed | Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies |
Myelodysplastic Syndromes (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00776503 | GFMVOR2007 | P1/P2 | completed | Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia |
| NCT00486720 | SAHA | P2 | terminated | Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) |
Non-small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00702572 | — | P1 | terminated | Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer |
| NCT00503971 | — | P1/P2 | terminated | Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. |
Non-Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00423449 | MK0683-058 | P1 | completed | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) |
| NCT00667082 | — | P1 | completed | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma |
Recurrent Non-small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00481078 | — | P2 | completed | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer |
| NCT00138203 | — | P2 | completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer |
Tumors (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00127127 | MK-0683-029 | P1 | completed | A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) |
| NCT00373490 | — | P1 | completed | A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) |
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00275080 | — | P1 | completed | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia |
| NCT00357708 | — | P1 | completed | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases |
GVHD (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06995521 | GVHD | P2 | not yet recruiting | Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population |
Mycosis Fungoides (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02943642 | Resimmune® | P2 | withdrawn | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides |
Pitt Hopkins Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07150026 | — | P1 | recruiting | An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome |
Rett Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07150013 | — | P1 | recruiting | Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome |
Primary Malignant Peripheral Nerve Sheath Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06693284 | — | Early P1 | recruiting | A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] |
HIV (Human Immunodeficiency Virus) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07217379 | DELIVER-02 | P1 | recruiting | The DART DELIVER-02 Study |
HPV-Related Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05608369 | HPV | P2 | withdrawn | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC |
Cushing's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04339751 | — | P2 | withdrawn | Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease |
Castration-Resistant Prostate Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06145633 | — | P2 | recruiting | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer |
HIV-1-infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05700630 | — | P1 | withdrawn | Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia |
Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05848687 | TINI 2 | P1/P2 | recruiting | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II |
Acute Myeloid Leukemia, in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05317403 | — | P1 | recruiting | Venetoclax to Augment Epigenetic Modification and Chemotherapy |
Recurrent Aggressive Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04220008 | — | P2 | withdrawn | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma |
Anatomic Stage IV Breast Cancer AJCC v8 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04190056 | — | P2 | terminated | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer |
Squamous Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04357873 | PEVOsq | P2 | completed | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations |
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03878524 | SMMART | P1 | terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial |
Hematologic Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03842696 | — | P1/P2 | active not recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation |
Uveal Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03022565 | — | Early P1 | withdrawn | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma |
Recurrent Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03259503 | — | P1 | completed | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant |
Breast Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03742245 | — | P1 | active not recruiting | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
Cutaneous T-Cell Lymphoma/Mycosis Fungoides (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03713320 | SOLAR | P2 | terminated | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides |
Refractory Epilepsy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03894826 | — | P2 | unknown | Voronistat in Pediatric Patients With Drug Resistant Epilepsy |
Leiomyosarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03509207 | SAHA | P2 | terminated | Vorinostat (SAHA) in Uterine Sarcoma |
Crohn's Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03167437 | — | P1/P2 | recruiting | An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab |
Alzheimer Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03056495 | VostatAD01 | P1 | terminated | Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease |
Grade 3b Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03150329 | — | P1 | active not recruiting | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. |
Acute Myelogenous Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03263936 | — | P1 | completed | Epigenetic Reprogramming in Relapse/Refractory AML |
Schizophrenia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03263533 | — | Early P1 | withdrawn | HDAC Inhibitor Augmentation to Clozapine |
Ewing Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04308330 | NYMC195 | P1 | recruiting | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies |
Central Nervous System Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03050450 | — | P1 | terminated | Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors |
Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02836548 | — | P1/P2 | completed | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma |
Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02638090 | NSCLC | P1/P2 | active not recruiting | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) |
Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02619253 | — | P1 | completed | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma |
HIV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02336074 | RIVER | P2 | completed | Research In Viral Eradication of HIV Reservoirs |
Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02538510 | — | P1/P2 | completed | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery |
Diffuse Intrinsic Pontine Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02420613 | — | P1 | completed | Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma |
Breast Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02395627 | — | P2 | terminated | Reversing Therapy Resistance With Epigenetic-Immune Modification |
Mixed Lineage Acute Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02419755 | — | P2 | terminated | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies |
Leukemia, Acute Myeloid (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02412475 | — | P1 | terminated | Epigenetic Reprogramming in Relapse AML |
Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02316340 | — | P2 | completed | Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer |
Acute HIV Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02475915 | — | P1/P2 | completed | Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection |
Pancreatic Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02349867 | — | P1 | completed | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer |
Graft vs Host Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01790568 | — | P2 | completed | Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant |
Neimann-Pick Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02124083 | — | P1/P2 | completed | Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 |
Von Hippel-Lindau Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02108002 | — | P1 | completed | Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) |
Acute Lymphoblastic Leukemia in Remission (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT02083250 | — | P1 | completed | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant |
HIV Infection (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01249443 | — | P1 | terminated | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection |
Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01879085 | GemTax | P1/P2 | completed | Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma |
Acute Myeloid Leukemia With 11q23-abnormality in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01550224 | AML | P2 | completed | Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) |
Recurrent Glioblastoma Multiforme (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01738646 | — | P2 | completed | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients |
Cutaneous T-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01728805 | — | P3 | completed | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL |
Follicular Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01500538 | VEIL | P2 | terminated | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) |
Stage II Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01695057 | — | N/A | withdrawn | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer |
Brain Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01600742 | — | P2 | terminated | Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis |
Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01578343 | ZOLINZA | P2 | terminated | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma |
Metastatic Uveal Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01587352 | — | P2 | active not recruiting | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye |
Adult B Acute Lymphoblastic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01567709 | — | P1 | completed | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
Children With Relapsed Solid Tumor, Lymphoma or Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01422499 | — | P1/P2 | completed | Vorinostat in Children |
Chronic Myelomonocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01522976 | — | P2 | active not recruiting | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia |
Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01174199 | — | P1 | terminated | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer |
Multiple Myeloma in Relapse (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01394354 | VBDD | P1/P2 | completed | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) |
Malignant Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01266031 | — | P1/P2 | completed | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma |
HIV Positive (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01365065 | — | P2 | unknown | Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy |
Stage I Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01194427 | — | P2 | terminated | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer |
Adult Solid Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01281176 | — | P1 | active not recruiting | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors |
Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01294670 | — | P1/P2 | completed | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors |
Brain Stem Glioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01236560 | — | P2/P3 | completed | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma |
Cutaneous Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01187446 | — | P1/P2 | terminated | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides |
Paranasal Sinus Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01267240 | — | P2 | terminated | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer |
Adult Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01342757 | — | N/A | completed | Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma |
Localized Unresectable Neuroblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01208454 | — | P1 | completed | Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma |
Ann Arbor Stage II Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00972478 | — | P1/P2 | active not recruiting | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma |
Stage IIIA Lung Non-Small Cell Cancer AJCC v7 (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01413750 | — | P2 | terminated | Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer |
AIDS-Related Plasmablastic Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01193842 | — | P1/P2 | completed | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas |
Adult Diffuse Large B-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00992446 | — | P2 | completed | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
Liver Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01075113 | — | P1 | completed | Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer |
Anaplastic Astrocytoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01189266 | — | P1/P2 | completed | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma |
Recurrent Oral Cavity Adenoid Cystic Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01175980 | — | P2 | completed | Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma |
Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00837174 | COMBOSTAT | P2 | withdrawn | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study |
Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00918489 | SAHA-I | P2 | completed | Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) |
Previously Treated Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01130506 | — | P1 | completed | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome |
Childhood Atypical Teratoid/Rhabdoid Tumor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01076530 | — | P1 | completed | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01045538 | X | P1/P2 | completed | Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP |
Stage III Squamous Cell Carcinoma of the Oropharynx (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01064921 | — | P1 | completed | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma |
Locally Advanced Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01059552 | NSCLC | P1 | completed | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
Ovarian Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00976183 | — | P1/P2 | terminated | Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma |
Sickle Cell Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01000155 | — | P2 | terminated | Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease |
Peripheral T-Cell Non-Hodgkin's Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00972842 | LenVoDex | P1/P2 | terminated | Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) |
Childhood Burkitt Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00994500 | — | P1 | completed | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
Adenocarcinoma of the Colon (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00942266 | — | P2 | completed | Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment |
Cutaneous T-cell Lymphoma Stage I (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00958074 | — | P2 | terminated | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma |
Recurrent Adult Soft Tissue Sarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00937495 | — | P2 | completed | Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma |
Chronic Lymphocytic Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00918723 | — | P1/P2 | completed | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma |
Non-Small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00821951 | — | P1 | completed | Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer |
Brain Metastases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00838929 | — | P1 | completed | Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases |
Aerodigestive Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00735826 | — | N/A | completed | A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer |
DS Stage I Plasma Cell Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00839956 | — | P2 | completed | Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant |
Medulloblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00867178 | — | P1 | completed | Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System |
Relapsed Lymphomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00785798 | — | P1/P2 | terminated | Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas |
Hematologic Malignancies (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00810602 | — | P1/P2 | completed | Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant |
Advanced Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00719875 | SAHA | P1 | completed | HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer |
Carcinoma, Non Small Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00798720 | — | P2 | completed | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer |
Multiple Myeloma and Plasma Cell Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00744354 | — | P1 | terminated | Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Recurrent B-Cell Non-Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00764517 | — | P2 | completed | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma |
Recurrent Mantle Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00703664 | — | P2 | completed | Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma |
Acute Myeloid Leukemia (AML) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00656617 | MDS | P2 | completed | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) |
Stage IIIA Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00662311 | — | P1/P2 | terminated | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery |
Prostate Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00589472 | TARGET | P2 | completed | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer |
Glioblastoma Multiforme (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00555399 | GBM | P1/P2 | terminated | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) |
Advanced Cancer Relapsed (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00632931 | COMPLETED | P1 | completed | A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) |
Adult Grade III Lymphomatoid Granulomatosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00499811 | — | P1 | completed | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
Leukemia, Myelocytic, Acute Myelodysplastic Syndromes (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00479232 | MK-0683-055 EXT1 | P1 | completed | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) |
Stage IIIB or IV Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00473889 | NSCLC | P2/P3 | terminated | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) |
Pelvic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00455351 | PRAVO | P1 | completed | Vorinostat and Palliative Radiotherapy |
Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00424775 | NSCLC | P1 | terminated | A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066) |
Esophageal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00537121 | — | P1 | completed | Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer |
Acute Erythroid Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00392353 | — | P1/P2 | active not recruiting | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00731952 | — | P1 | completed | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer |
Localized Transitional Cell Cancer of the Renal Pelvis and Ureter (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00363883 | — | P2 | terminated | Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium |
Recurrent Prostate Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00330161 | — | P2 | completed | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer |
Recurrent Renal Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00324740 | — | P1/P2 | terminated | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer |
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00331513 | — | P1 | completed | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes |
Adult Nasal Type Extranodal NK/T-Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00336063 | — | P1 | active not recruiting | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma |
Clear Cell Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00324870 | — | P1/P2 | completed | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer |
Carcinoma, Non-Small-Cell Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00251589 | — | P1/P2 | terminated | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) |
Adult Acute Erythroid Leukemia (M6) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00305773 | — | P2 | completed | Vorinostat in Treating Patients With Acute Myeloid Leukemia |
Blastic Phase Chronic Myelogenous Leukemia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00278330 | — | P1 | completed | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia |
Insular Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00134043 | — | P2 | completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer |
Refractory Multiple Myeloma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00310024 | — | P1 | completed | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma |
Primary Peritoneal Cavity Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00132067 | — | P2 | completed | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer |
Recurrent Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00278395 | — | P2 | completed | Vorinostat in Treating Patients With Kidney Cancer |
Adult Favorable Prognosis Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00132028 | — | P2 | completed | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma |
Ciliary Body and Choroid Melanoma, Medium/Large Size (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00121225 | — | P2 | completed | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma |
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00253630 | — | P2 | completed | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma |
Childhood Acute Promyelocytic Leukemia (M3) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00217412 | — | P1 | completed | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia |
Recurrent Colon Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00138177 | — | P1 | completed | Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors |
Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00128102 | MK-0683-014 | P3 | completed | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) |
B-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00097929 | — | P2 | completed | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) |
Cutaneous T-cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00091559 | — | P2 | completed | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) |
Cancer, Advanced (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00750178 | — | P1 | completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008) |
Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00045006 | — | P1 | completed | Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer |
Lymphoma, T-Cell, Cutaneous (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT00419367 | — | N/A | no longer available | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) |
Malignant Pleural Mesothelioma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT01353482 | MESO-02 | P1/P2 | withdrawn | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma |
Vorinostat pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| Myeloma XI | NCT01554852 | P3 | unknown | Multiple Myeloma | 4,420 | PMID 26282654 |
| MK-0683 | NCT00773747 | P3 | completed | Multiple Myeloma | 637 | PMID 24055414 |
| MK-0683-014 | NCT00128102 | P3 | completed | Mesothelioma | 661 | PMID 25800891 |
| PEDS-PLAN | NCT02559778 | P2 | recruiting | Neuroblastoma | 500 | — |
| NANT 2021-02 | NCT07261241 | P2 | not yet recruiting | Neuroblastoma | 118 | — |
| GVHD | NCT06995521 | P2 | not yet recruiting | GVHD | 55 | — |
| Resimmune® | NCT02943642 | P2 | withdrawn | Mycosis Fungoides | 0 | PMID 25795722 |
| HPV | NCT05608369 | P2 | withdrawn | HPV-Related Squamous Cell Carcinoma | 0 | — |
| OPTIMUM | NCT03561259 | P2 | unknown | Neuroblastoma | 60 | — |
| PEVOsq | NCT04357873 | P2 | completed | Squamous Cell Lung Cancer | 112 | PMID 41468684 |
| RIVER | NCT02336074 | P2 | completed | HIV | 60 | PMID 23516360 |
| N2011-01 | NCT02035137 | P2 | completed | Neuroblastoma | 114 | PMID 34270348 |
| RAvVA | NCT01617226 | P2 | completed | Leukemia, Myeloid, Acute | 260 | PMID 10694544 |
| SOLAR | NCT03713320 | P2 | terminated | Cutaneous T-Cell Lymphoma/Mycosis Fungoides | 37 | PMID 33085815 |
| MK-0683 | NCT00875056 | P2 | completed | Lymphoma | 56 | PMID 24617454 |
| SAHA | NCT03509207 | P2 | terminated | Leiomyosarcoma | 3 | — |
| MUKfour | NCT01720875 | P2 | completed | Multiple Myeloma | 16 | PMID 33478922 |
| AML | NCT00948064 | P2 | completed | Leukemia | 110 | PMID 27795561 |
| ZOLINZA | NCT01578343 | P2 | terminated | Mantle Cell Lymphoma | 20 | — |
| GFM-AZA-VOR | NCT01748240 | P2 | terminated | Myelodysplastic Syndrome | 21 | — |
| AML | NCT01550224 | P2 | completed | Acute Myeloid Leukemia With 11q23-abnormality in Relapse | 23 | — |
| VEIL | NCT01500538 | P2 | terminated | Follicular Lymphoma | 1 | — |
| MDS | NCT00656617 | P2 | completed | Acute Myeloid Leukemia (AML) | 106 | — |
| SAHA-I | NCT00918489 | P2 | completed | Soft Tissue Sarcoma | 40 | PMID 27367154 |
| ALL | NCT01312818 | P2 | terminated | Acute Lymphoblastic Leukemia | 2 | — |
| COMBOSTAT | NCT00837174 | P2 | withdrawn | Non-Hodgkin Lymphoma | 0 | — |
| MK0683 | NCT00773838 | P2 | completed | Relapsed or Refractory Multiple Myeloma | 143 | PMID 27025160 |
| ZLd_Ld | NCT01501370 | P2 | withdrawn | Multiple Myeloma | 0 | — |
| TARGET | NCT00589472 | P2 | completed | Prostate Adenocarcinoma | 19 | — |
| MK-0683 | NCT00907738 | P2 | completed | Advanced Cancer | 27 | PMID 19951879 |
| SAHA | NCT00486720 | P2 | terminated | Myelodysplastic Syndromes | 22 | — |
| SAHA | NCT00126451 | P2 | terminated | Breast Cancer | 16 | PMID 18425418 |
Terminated and withdrawn Vorinostat trials (74)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT02943642withdrawnSafety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides
- NCT05608369withdrawnVorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC
- NCT04339751withdrawnEffect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease
- NCT05700630withdrawnPh1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
- NCT03056495terminatedClinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease
- NCT04190056terminatedPembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer
- NCT04220008withdrawnVorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma
- NCT03878524terminatedSerial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
- NCT03713320terminatedSOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides
- NCT03022565withdrawnVorinostat in Patients With Class 2 High Risk Uveal Melanoma
- NCT00555399terminatedVorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
- NCT02395627terminatedReversing Therapy Resistance With Epigenetic-Immune Modification
- NCT03198559terminatedCombination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART
- NCT02589145terminatedLenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype
- NCT03263533withdrawnHDAC Inhibitor Augmentation to Clozapine
- NCT03509207terminatedVorinostat (SAHA) in Uterine Sarcoma
- NCT03050450terminatedStudy of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
- NCT02707900terminatedPilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection
- NCT01249443terminatedPaclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection
- NCT02412475terminatedEpigenetic Reprogramming in Relapse AML
- NCT00857324terminatedStudy of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients
- NCT01492881withdrawnStudy of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
- NCT02419755terminatedBortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies
- NCT01267240terminatedCapecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer
- NCT00702572terminatedCarboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer
- NCT01174199terminatedTemsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
- NCT01578343terminatedVorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma
- NCT01695057withdrawnVorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer
- NCT00910000terminatedVorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer
- NCT01748240terminatedAddition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure
- NCT01483690terminatedA Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
- NCT00744354terminatedVorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma
- NCT01000155terminatedEfficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease
- NCT01110876terminatedPhase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
- NCT01500538terminatedA Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL)
- NCT00324740terminatedVorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
- NCT01187446terminatedLow-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
- NCT01600742terminatedVorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis
- NCT00948688terminatedVorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas
- NCT00958074terminatedVorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
- NCT01378481terminatedHigh-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma
- NCT01413750terminatedCarboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer
- NCT01312818terminatedBortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
- NCT00882206terminatedPre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia
- NCT01608139withdrawnStudy of Curcumin, Vorinostat, and Sorafenib
- NCT01118975terminatedGCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
- NCT00976183terminatedPaclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma
- NCT00972842terminatedLenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL)
- NCT00702962terminatedCarboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer
- NCT00837174withdrawnRelapsed and/or Refractory Non-Hodgkin Lymphoma Study
- NCT00818649terminatedBortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
- NCT01501370withdrawnVorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy
- NCT00503971terminatedPhase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.
- NCT01194427terminatedA Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer
- NCT00785798terminatedVorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
- NCT00662311terminatedVorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery
- NCT01386398withdrawnVorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma
- NCT01353482withdrawnA Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
- NCT00363883terminatedVorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium
- NCT00831493terminatedVorinostat Plus Radiation Therapy in Pancreatic Cancer
- NCT01116154terminatedVorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
- NCT00810576terminatedCombination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
- NCT00697476terminatedStudy of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC
- NCT00801151terminatedVorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
- NCT00565227terminatedPhase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies.
- NCT00486720terminatedPhase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064)
- NCT00473889terminatedA Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
- NCT00127101terminatedAn Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED)
- NCT00673153terminatedVorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
- NCT00132002terminatedSuberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
- NCT00251589terminatedA Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025)
- NCT00424775terminatedA Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066)
- NCT00109109terminatedA Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
- NCT00126451terminatedA Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
All Vorinostat trials (272)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT02559778 | PEDS-PLAN | Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | P2 | recruiting | 500 | Giselle Sholler | Sep 2015 |
| NCT03167437 | An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab | P1/P2 | recruiting | 35 | National Institute of Allergy and Infectious Diseases (NIAID) | Oct 2017 | |
| NCT05848687 | TINI 2 | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | P1/P2 | recruiting | 90 | Tanja Andrea Gruber | Nov 2023 |
| NCT02553460 | ALL | Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I | P1/P2 | active not recruiting | 50 | St. Jude Children's Research Hospital | Jan 2016 |
| NCT07261241 | NANT 2021-02 | NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab | P2 | not yet recruiting | 118 | New Approaches to Neuroblastoma Therapy Consortium | Jul 2026 |
| NCT03117751 | Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma | P2/P3 | active not recruiting | 790 | St. Jude Children's Research Hospital | Mar 2017 | |
| NCT06995521 | GVHD | Vorinostat for Graft-versus-host Disease (GVHD) Prevention in Non-Malignant Adolescent and Young Adults (AYA) Population | P2 | not yet recruiting | 55 | Sung Won Choi | May 2026 |
| NCT04308330 | NYMC195 | Vorinostat in Combination With Chemotherapy in Relapsed/Refractory Solid Tumors and CNS Malignancies | P1 | recruiting | 30 | New York Medical College | Mar 2017 |
| NCT06145633 | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | P2 | recruiting | 15 | Fred Hutchinson Cancer Center | Sep 2024 | |
| NCT00268385 | Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | P1 | active not recruiting | 83 | National Cancer Institute (NCI) | Dec 2005 | |
| NCT01281176 | High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors | P1 | active not recruiting | 20 | National Cancer Institute (NCI) | Feb 2011 | |
| NCT01522976 | Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia | P2 | active not recruiting | 282 | National Cancer Institute (NCI) | Mar 2012 | |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | P1 | active not recruiting | 18 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT07150026 | An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome | P1 | recruiting | 5 | Unravel Biosciences, Inc. | Mar 2026 | |
| NCT07150013 | Rett REVOLUTION Trial: An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Rett Syndrome | P1 | recruiting | 15 | Unravel Biosciences, Inc. | Mar 2026 | |
| NCT00972478 | Vorinostat, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma | P1/P2 | active not recruiting | 83 | National Cancer Institute (NCI) | Nov 2010 | |
| NCT07217379 | DELIVER-02 | The DART DELIVER-02 Study | P1 | recruiting | 24 | University of North Carolina, Chapel Hill | Oct 2025 |
| NCT00616967 | Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer | P2 | active not recruiting | 68 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | May 2008 | |
| NCT05317403 | Venetoclax to Augment Epigenetic Modification and Chemotherapy | P1 | recruiting | 40 | Medical College of Wisconsin | Mar 2023 | |
| NCT06693284 | A Window of Opportunity Trial of Mirdametinib Plus Vorinostat for NF1 Associated, H3K27 Trimethylation Deficient Malignant Peripheral Nerve Sheath Tumor [MPNST] | Early P1 | recruiting | 8 | University of Minnesota | Nov 2025 | |
| NCT01587352 | Vorinostat in Treating Patients With Metastatic Melanoma of the Eye | P2 | active not recruiting | 40 | National Cancer Institute (NCI) | May 2012 | |
| NCT00392353 | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia | P1/P2 | active not recruiting | 135 | National Cancer Institute (NCI) | Nov 2006 | |
| NCT03742245 | Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer | P1 | active not recruiting | 28 | The Methodist Hospital Research Institute | Jun 2019 | |
| NCT03843528 | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation | P1 | active not recruiting | 15 | Johns Hopkins All Children's Hospital | May 2019 | |
| NCT01087554 | Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer | P1 | active not recruiting | 249 | M.D. Anderson Cancer Center | Mar 2010 | |
| NCT02638090 | NSCLC | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | P1/P2 | active not recruiting | 120 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2016 |
| NCT01297764 | QUAD | A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma | P1/P2 | active not recruiting | 17 | Hackensack Meridian Health | Apr 2011 |
| NCT03150329 | Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. | P1 | active not recruiting | 52 | City of Hope Medical Center | Jul 2017 | |
| NCT02943642 | Resimmune® | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | P2 | withdrawn | 0 | Virogen Biotechnology Inc. | May 2026 |
| NCT03842696 | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation | P1/P2 | active not recruiting | 43 | University of Michigan Rogel Cancer Center | Feb 2020 | |
| NCT05608369 | HPV | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC | P2 | withdrawn | 0 | Case Comprehensive Cancer Center | Jun 2025 |
| NCT03259503 | Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant | P1 | completed | 50 | M.D. Anderson Cancer Center | Sep 2019 | |
| NCT03561259 | OPTIMUM | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects | P2 | unknown | 60 | Jubilant DraxImage Inc. | Oct 2019 |
| NCT04339751 | Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease | P2 | withdrawn | 0 | National Institute of Neurological Disorders and Stroke (NINDS) | Apr 2025 | |
| NCT02420613 | Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma | P1 | completed | 18 | M.D. Anderson Cancer Center | Oct 2015 | |
| NCT04357873 | PEVOsq | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations | P2 | completed | 112 | UNICANCER | Oct 2020 |
| NCT05700630 | Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia | P1 | withdrawn | 0 | Masonic Cancer Center, University of Minnesota | Jul 2024 | |
| NCT03056495 | VostatAD01 | Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease | P1 | terminated | 9 | German Center for Neurodegenerative Diseases (DZNE) | Sep 2017 |
| NCT03332667 | MIBG With Dinutuximab +/- Vorinostat | P1 | completed | 45 | New Approaches to Neuroblastoma Therapy Consortium | Sep 2018 | |
| NCT01236560 | Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | P2/P3 | completed | 101 | National Cancer Institute (NCI) | Jan 2011 | |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | P1/P2 | completed | 33 | The Netherlands Cancer Institute | Jun 2016 | |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | P1/P2 | completed | 50 | University of Washington | Oct 2015 | |
| NCT03382834 | Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors | P2 | completed | 31 | National Institute of Allergy and Infectious Diseases (NIAID) | Apr 2018 | |
| NCT03426891 | Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma | P1 | completed | 21 | H. Lee Moffitt Cancer Center and Research Institute | Mar 2018 | |
| NCT04190056 | Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer | P2 | terminated | 1 | University of California, San Francisco | Mar 2021 | |
| NCT02336074 | RIVER | Research In Viral Eradication of HIV Reservoirs | P2 | completed | 60 | Imperial College London | Nov 2015 |
| NCT02619253 | Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma | P1 | completed | 52 | Nabil Adra | Feb 2016 | |
| NCT01023737 | Hydroxychloroquine + Vorinostat in Advanced Solid Tumors | P1 | completed | 72 | The University of Texas Health Science Center at San Antonio | Nov 2009 | |
| NCT01554852 | Myeloma XI | Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients | P3 | unknown | 4,420 | University of Leeds | May 2010 |
| NCT03212989 | XTRA | Study to Evaluate Effects of Vorinostat and HXTC on Persistent HIV-1 Infection in HIV-Infected Subjects Started on Antiretroviral Therapy (ART) | P1 | completed | 17 | University of North Carolina, Chapel Hill | Jun 2017 |
| NCT01193842 | Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas | P1/P2 | completed | 107 | National Cancer Institute (NCI) | Oct 2010 | |
| NCT02349867 | Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer | P1 | completed | 23 | Virginia Commonwealth University | Jan 2015 | |
| NCT03263936 | Epigenetic Reprogramming in Relapse/Refractory AML | P1 | completed | 37 | Therapeutic Advances in Childhood Leukemia Consortium | Jul 2017 | |
| NCT00867178 | Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System | P1 | completed | 33 | National Cancer Institute (NCI) | Feb 2009 | |
| NCT02083250 | Fludarabine Phosphate, Clofarabine, and Busulfan With Vorinostat in Treating Patients With Acute Leukemia in Remission or Relapse Undergoing Donor Stem Cell Transplant | P1 | completed | 70 | M.D. Anderson Cancer Center | Mar 2014 | |
| NCT04220008 | Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma | P2 | withdrawn | 0 | M.D. Anderson Cancer Center | Oct 2021 | |
| NCT01189266 | Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma | P1/P2 | completed | 79 | National Cancer Institute (NCI) | Aug 2010 | |
| NCT01038388 | A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma | P1 | completed | 30 | Emory University | Jan 2010 | |
| NCT01879085 | GemTax | Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma | P1/P2 | completed | 37 | Melissa Burgess, MD | Sep 2013 |
| NCT02035137 | N2011-01 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat | P2 | completed | 114 | New Approaches to Neuroblastoma Therapy Consortium | Jul 2014 |
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | P3 | completed | 372 | Kyowa Kirin, Inc. | Nov 2012 | |
| NCT01266057 | Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer | P1 | completed | 143 | M.D. Anderson Cancer Center | Apr 2011 | |
| NCT03803605 | Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons | P1 | completed | 15 | University of North Carolina, Chapel Hill | Feb 2019 | |
| NCT01617226 | RAvVA | Randomised Study of Azacitidine Versus Azacitidine With Vorinostat in Patients With AML or High Risk MDS | P2 | completed | 260 | University of Birmingham | Sep 2012 |
| NCT03878524 | SMMART | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | P1 | terminated | 2 | OHSU Knight Cancer Institute | Apr 2020 |
| NCT01294670 | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | P1/P2 | completed | 27 | Memorial Sloan Kettering Cancer Center | Feb 2011 | |
| NCT03713320 | SOLAR | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides | P2 | terminated | 37 | miRagen Therapeutics, Inc. | Apr 2019 |
| NCT03894826 | Voronistat in Pediatric Patients With Drug Resistant Epilepsy | P2 | unknown | 12 | University of Calgary | Dec 2018 | |
| NCT00729118 | Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | P1 | completed | 19 | Ohio State University Comprehensive Cancer Center | Sep 2008 | |
| NCT01720602 | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | N/A | completed | 15 | University of Washington | Nov 2012 | |
| NCT03022565 | Vorinostat in Patients With Class 2 High Risk Uveal Melanoma | Early P1 | withdrawn | 0 | University of Miami | Jan 2020 | |
| NCT00555399 | GBM | Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM) | P1/P2 | terminated | 55 | M.D. Anderson Cancer Center | Nov 2007 |
| NCT02042989 | MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies | P1 | completed | 68 | M.D. Anderson Cancer Center | Jun 2014 | |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | P1/P2 | completed | 125 | National Cancer Institute (NCI) | Jul 2009 | |
| NCT00992446 | Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma | P2 | completed | 27 | Fred Hutchinson Cancer Center | Sep 2010 | |
| NCT01059552 | NSCLC | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | P1 | completed | 18 | Fox Chase Cancer Center | Dec 2009 |
| NCT01084057 | Ixabepilone and Vorinostat in Treating Patients With Metastatic Breast Cancer | P1 | completed | 56 | City of Hope Medical Center | May 2010 | |
| NCT01075113 | Sorafenib and Vorinostat in Treating Patients With Advanced Liver Cancer | P1 | completed | 16 | Virginia Commonwealth University | Aug 2010 | |
| NCT02395627 | Reversing Therapy Resistance With Epigenetic-Immune Modification | P2 | terminated | 38 | University of California, San Francisco | May 2015 | |
| NCT03198559 | Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART | P1/P2 | terminated | 5 | University of Melbourne | Aug 2017 | |
| NCT02589145 | Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype | P1/P2 | terminated | 8 | M.D. Anderson Cancer Center | Jun 2016 | |
| NCT03263533 | HDAC Inhibitor Augmentation to Clozapine | Early P1 | withdrawn | 0 | Virginia Commonwealth University | Apr 2017 | |
| NCT00875056 | MK-0683 | Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103) | P2 | completed | 56 | Merck Sharp & Dohme LLC | Apr 2009 |
| NCT03509207 | SAHA | Vorinostat (SAHA) in Uterine Sarcoma | P2 | terminated | 3 | Medical University of Graz | Dec 2017 |
| NCT03050450 | Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors | P1 | terminated | 8 | Johns Hopkins All Children's Hospital | Aug 2016 | |
| NCT01593670 | Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes | P2 | completed | 9 | Masonic Cancer Center, University of Minnesota | Mar 2013 | |
| NCT02108002 | Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) | P1 | completed | 7 | National Institute of Neurological Disorders and Stroke (NINDS) | Apr 2014 | |
| NCT01720875 | MUKfour | Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour) | P2 | completed | 16 | University of Leeds | Aug 2013 |
| NCT01175980 | Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma | P2 | completed | 30 | National Cancer Institute (NCI) | Aug 2010 | |
| NCT02707900 | VORVAX | Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection | P1 | terminated | 6 | University of North Carolina, Chapel Hill | Mar 2016 |
| NCT02316340 | Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer | P2 | completed | 42 | The University of Texas Health Science Center at San Antonio | Feb 2015 | |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | P1 | completed | 34 | National Cancer Institute (NCI) | Apr 2012 | |
| NCT02151721 | VICTORY-J | Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer | P1 | unknown | 12 | Kanazawa University | Jun 2014 |
| NCT01365065 | Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy | P2 | unknown | 20 | Bayside Health | May 2011 | |
| NCT01249443 | Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | P1 | terminated | 17 | AIDS Malignancy Consortium | Nov 2013 | |
| NCT00703664 | Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma | P2 | completed | 65 | National Cancer Institute (NCI) | Jul 2008 | |
| NCT01983969 | Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma | P1/P2 | completed | 61 | M.D. Anderson Cancer Center | Nov 2013 | |
| NCT01064921 | Ph I Vorinostat in the Treatment of Advanced Staged Oropharyngeal Squamous Cell Carcinoma | P1 | completed | 27 | Ohio State University Comprehensive Cancer Center | Jan 2010 | |
| NCT01790568 | Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant | P2 | completed | 26 | University of Michigan Rogel Cancer Center | Dec 2014 | |
| NCT00948064 | AML | Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | P2 | completed | 110 | M.D. Anderson Cancer Center | Sep 2009 |
| NCT02412475 | Epigenetic Reprogramming in Relapse AML | P1 | terminated | 3 | Michael Burke | Feb 2015 | |
| NCT01802333 | Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia | P3 | completed | 754 | National Cancer Institute (NCI) | Feb 2013 | |
| NCT00720876 | Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma | P2 | completed | 30 | City of Hope Medical Center | Jul 2008 | |
| NCT01339871 | Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies | P1 | completed | 152 | M.D. Anderson Cancer Center | Apr 2011 | |
| NCT00857324 | Study of Vorinostat Plus Melphalan and Prednisone (Zmp) in Advanced, Refractory Multiple Myeloma Patients | P1/P2 | terminated | 18 | Tiziana Marangon | Mar 2009 | |
| NCT00839956 | Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant | P2 | completed | 31 | Fred Hutchinson Cancer Center | Feb 2009 | |
| NCT00764517 | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | P2 | completed | 57 | OHSU Knight Cancer Institute | Aug 2008 | |
| NCT01422499 | Vorinostat in Children | P1/P2 | completed | 50 | National Center for Tumor Diseases, Heidelberg | Mar 2012 | |
| NCT00667615 | DLBCL | Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) | P1/P2 | completed | 30 | Memorial Sloan Kettering Cancer Center | Apr 2008 |
| NCT01534260 | Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype | P1/P2 | completed | 37 | Hamid Sayar | Feb 2012 | |
| NCT01492881 | Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma | P2 | withdrawn | 0 | UNC Lineberger Comprehensive Cancer Center | Apr 2012 | |
| NCT01266031 | Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma | P1/P2 | completed | 96 | National Cancer Institute (NCI) | Jul 2011 | |
| NCT02419755 | Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies | P2 | terminated | 12 | St. Jude Children's Research Hospital | Apr 2015 | |
| NCT02124083 | Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1 | P1/P2 | completed | 12 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Apr 2014 | |
| NCT01267240 | Capecitabine and Vorinostat in Treating Patients With Recurrent and/or Metastatic Head and Neck Cancer | P2 | terminated | 25 | National Cancer Institute (NCI) | Dec 2010 | |
| NCT00918723 | Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | P1/P2 | completed | 40 | Fred Hutchinson Cancer Center | Jun 2009 | |
| NCT01120834 | DLBCL | Study of 5-azacitidine in Combination With Vorinostat in Patients With Relapsed or Refractory Diffuse Large b Cell Lymphoma (DLBCL) | P1/P2 | completed | 17 | Weill Medical College of Cornell University | Sep 2010 |
| NCT00702572 | Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer | P1 | terminated | 25 | Milton S. Hershey Medical Center | Apr 2008 | |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | P1 | terminated | 13 | Roswell Park Cancer Institute | Feb 2012 | |
| NCT01153672 | Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy | N/A | completed | 8 | University of Washington | Nov 2010 | |
| NCT01502085 | RZD | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens | P1/P2 | completed | 25 | Hackensack Meridian Health | Dec 2011 |
| NCT00253630 | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | P2 | completed | 37 | National Cancer Institute (NCI) | Sep 2005 | |
| NCT01045538 | X | Study of Vorinostat Plus Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer: Zolinza+XP | P1/P2 | completed | 45 | Asan Medical Center | Feb 2010 |
| NCT02475915 | Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection | P1/P2 | completed | 15 | SEARCH Research Foundation | Jan 2015 | |
| NCT01319383 | The Effect of Vorinostat on HIV RNA Expression in the Resting CD4+ T Cells of HIV+ Pts on Stable ART | P1/P2 | completed | 25 | University of North Carolina, Chapel Hill | Feb 2011 | |
| NCT01738646 | Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients | P2 | completed | 48 | Duke University | Jan 2013 | |
| NCT01578343 | ZOLINZA | Vorinostat Plus FND in Relapsed or Refractory Mantle Cell Lymphoma | P2 | terminated | 20 | Samsung Medical Center | Jun 2012 |
| NCT01394354 | VBDD | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) | P1/P2 | completed | 34 | University Hospital Freiburg | Aug 2011 |
| NCT01695057 | Vorinostat Before Surgery in Treating Patients With Triple-Negative Breast Cancer | N/A | withdrawn | 0 | University of Southern California | Oct 2012 | |
| NCT00910000 | Vorinostat, Carboplatin and Gemcitabine in Women With Recurrent, Platinum-Sensitive Ovarian Cancer | P1/P2 | terminated | 15 | Dana-Farber Cancer Institute | Jun 2009 | |
| NCT01421173 | SCT | Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | P1 | completed | 78 | M.D. Anderson Cancer Center | Aug 2011 |
| NCT00788112 | Vorinostat in Treating Women With Ductal Carcinoma in Situ of the Breast | P1 | completed | 17 | University of California, San Francisco | Jul 2009 | |
| NCT01748240 | GFM-AZA-VOR | Addition of Vorinostat to Azacitidine in Higher Risk MDS a Phase II add-on Study in Patients With Azacitidine Failure | P2 | terminated | 21 | Groupe Francophone des Myelodysplasies | Mar 2013 |
| NCT01483690 | A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | P1/P2 | terminated | 23 | Therapeutic Advances in Childhood Leukemia Consortium | Dec 2011 | |
| NCT00946673 | SRS | Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer | P1 | completed | 17 | Stanford University | Jun 2009 |
| NCT00773747 | MK-0683 | Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) | P3 | completed | 637 | Merck Sharp & Dohme LLC | Dec 2008 |
| NCT00744354 | Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma | P1 | terminated | 32 | UNC Lineberger Comprehensive Cancer Center | Oct 2008 | |
| NCT00838929 | Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases | P1 | completed | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Mar 2009 | |
| NCT00691210 | SAHA | Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies | P1 | completed | 40 | Columbia University | Jun 2008 |
| NCT01019850 | N2007-03 | N2007-03: Vorinostat and 131-I MIBG in Treating Patients With Resistant or Relapsed Neuroblastoma | P1 | completed | 27 | New Approaches to Neuroblastoma Therapy Consortium | Mar 2010 |
| NCT01276717 | Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma | P1 | completed | 20 | University of Rochester | Jan 2011 | |
| NCT00416130 | Clinical Trial of SAHA in Patients With Breast Cancer | P1/P2 | unknown | 49 | National University Hospital, Singapore | Jan 2007 | |
| NCT01550224 | AML | Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) | P2 | completed | 23 | Steven E. Coutre | May 2013 |
| NCT01000155 | Efficacy of Vorinostat to Induce Fetal Hemoglobin in Sickle Cell Disease | P2 | terminated | 5 | Dana-Farber Cancer Institute | Oct 2009 | |
| NCT00275080 | Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia | P1 | completed | 80 | National Cancer Institute (NCI) | Feb 2006 | |
| NCT01110876 | GBM | Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | P1/P2 | terminated | 21 | M.D. Anderson Cancer Center | Jun 2011 |
| NCT01500538 | VEIL | A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) | P2 | terminated | 1 | Peter MacCallum Cancer Centre, Australia | Oct 2012 |
| NCT00574587 | Trial for Locally Advanced Breast Cancer Using Vorinostat Plus Chemotherapy | P1/P2 | completed | 55 | Albert Einstein College of Medicine | Dec 2007 | |
| NCT00324740 | Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer | P1/P2 | terminated | 14 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | P2 | completed | 12 | National Cancer Institute (NCI) | Jun 2013 | |
| NCT01169532 | Ridaforolimus and Vorinostat in Treating Patients With Advanced Solid Tumors or Lymphoma | P1 | completed | 16 | Fox Chase Cancer Center | Oct 2010 | |
| NCT00731952 | Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer | P1 | completed | 21 | University of Virginia | Jun 2006 | |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | P1/P2 | terminated | 28 | Stanford University | Dec 2010 | |
| NCT00656617 | MDS | Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) | P2 | completed | 106 | M.D. Anderson Cancer Center | Apr 2008 |
| NCT01600742 | Vorinostat and Concurrent Whole Brain Radiotherapy for Brain Metastasis | P2 | terminated | 4 | National Taiwan University Hospital | Aug 2012 | |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | P1/P2 | terminated | 10 | Massachusetts General Hospital | Aug 2009 | |
| NCT00958074 | Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma | P2 | terminated | 11 | University of Washington | Jul 2009 | |
| NCT00324870 | Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer | P1/P2 | completed | 37 | National Cancer Institute (NCI) | Feb 2006 | |
| NCT00875745 | AML | Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | P1 | completed | 15 | Indiana University | Apr 2009 |
| NCT00918489 | SAHA-I | Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic Soft Tissue Sarcoma (STS) | P2 | completed | 40 | Heidelberg University | May 2010 |
| NCT00895934 | Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML | P1/P2 | completed | 52 | National Cancer Institute (NCI) | May 2009 | |
| NCT01378481 | High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | P1 | terminated | 30 | National Cancer Institute (NCI) | Jun 2012 | |
| NCT00642954 | MM | Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074) | P1 | completed | 31 | Merck Sharp & Dohme LLC | Feb 2008 |
| NCT00810602 | Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant | P1/P2 | completed | 61 | Pavan Reddy, MD | Jan 2009 | |
| NCT00762255 | A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma | P1 | completed | 19 | H. Lee Moffitt Cancer Center and Research Institute | Sep 2008 | |
| NCT00719875 | SAHA | HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer | P1 | completed | 24 | Yale University | Dec 2008 |
| NCT00537121 | Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer | P1 | completed | 23 | Roswell Park Cancer Institute | Nov 2006 | |
| NCT00121225 | Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma | P2 | completed | 32 | National Cancer Institute (NCI) | Sep 2005 | |
| NCT00561418 | Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma | P1 | completed | 23 | Ohio State University Comprehensive Cancer Center | Nov 2007 | |
| NCT00262834 | Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I -III Breast Cancer | P2 | completed | 54 | National Cancer Institute (NCI) | Oct 2005 | |
| NCT01838187 | Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma | — | no longer available | 0 | Children's Hospital Medical Center, Cincinnati | — | |
| NCT01413750 | Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | P2 | terminated | 23 | National Cancer Institute (NCI) | Nov 2010 | |
| NCT00983268 | Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer | P1 | completed | 21 | Vanderbilt-Ingram Cancer Center | Oct 2009 | |
| NCT01312818 | ALL | Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) | P2 | terminated | 2 | Masonic Cancer Center, University of Minnesota | Jun 2011 |
| NCT00882206 | Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia | P2 | terminated | 15 | Masonic Cancer Center, University of Minnesota | Apr 2009 | |
| NCT00787527 | SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma | P1/P2 | completed | 14 | M.D. Anderson Cancer Center | Nov 2008 | |
| NCT01608139 | Study of Curcumin, Vorinostat, and Sorafenib | P1 | withdrawn | 0 | M.D. Anderson Cancer Center | Nov 2012 | |
| NCT01118975 | GCC 0845 | GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers | P1/P2 | terminated | 12 | University of Maryland, Baltimore | Mar 2010 |
| NCT00976183 | Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma | P1/P2 | terminated | 18 | Gynecologic Oncology Associates | Oct 2009 | |
| NCT00798720 | Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer | P2 | completed | 18 | University of Wisconsin, Madison | Dec 2008 | |
| NCT00365599 | Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer | P2 | completed | 43 | H. Lee Moffitt Cancer Center and Research Institute | Feb 2006 | |
| NCT00972842 | LenVoDex | Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) | P1/P2 | terminated | 20 | Arbeitsgemeinschaft medikamentoese Tumortherapie | Sep 2009 |
| NCT00821951 | Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer | P1 | completed | 17 | Yale University | May 2009 | |
| NCT00735826 | A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer | N/A | completed | 10 | Dartmouth-Hitchcock Medical Center | Mar 2009 | |
| NCT00702962 | Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer | P1/P2 | terminated | 8 | Milton S. Hershey Medical Center | Sep 2008 | |
| NCT01342757 | Magnetic Resonance Spectroscopy Imaging in Predicting Response to Vorinostat and Temozolomide in Patients With Recurrent or Progressive Glioblastoma | N/A | completed | 12 | National Cancer Institute (NCI) | Dec 2010 | |
| NCT00837174 | COMBOSTAT | Relapsed and/or Refractory Non-Hodgkin Lymphoma Study | P2 | withdrawn | 0 | The Methodist Hospital Research Institute | Jun 2010 |
| NCT00818649 | Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia | P2 | terminated | 16 | Masonic Cancer Center, University of Minnesota | Jan 2009 | |
| NCT00127140 | SAHA | A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) | P1 | completed | 10 | Merck Sharp & Dohme LLC | Jun 2005 |
| NCT00858234 | MK-0683-098 | Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) | P1 | completed | 9 | Merck Sharp & Dohme LLC | Feb 2009 |
| NCT00773838 | MK0683 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | P2 | completed | 143 | Merck Sharp & Dohme LLC | Dec 2008 |
| NCT00635791 | Phase I Study of Vorinostat and Sorafenib in Advanced Cancer | P1 | completed | 36 | University of Colorado, Denver | Mar 2008 | |
| NCT00479232 | MK-0683-055 EXT1 | Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1) | P1 | completed | 71 | Merck Sharp & Dohme LLC | Jun 2007 |
| NCT01501370 | ZLd_Ld | Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy | P2 | withdrawn | 0 | Tiziana Marangon | Jan 2012 |
| NCT00942266 | Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment | P2 | completed | 58 | Roswell Park Cancer Institute | Jul 2009 | |
| NCT00503971 | Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. | P1/P2 | terminated | 33 | Spanish Lung Cancer Group | May 2008 | |
| NCT00368875 | Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer | P1/P2 | completed | 54 | National Cancer Institute (NCI) | Jul 2006 | |
| NCT01194427 | A Study of Vorinostat and Tamoxifen in Newly Diagnosed Breast Cancer | P2 | terminated | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Mar 2011 | |
| NCT00776503 | GFMVOR2007 | Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia | P1/P2 | completed | 52 | Groupe Francophone des Myelodysplasies | May 2008 |
| NCT00128102 | MK-0683-014 | Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (MK-0683-014) | P3 | completed | 661 | Merck Sharp & Dohme LLC | Jun 2005 |
| NCT00785798 | Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas | P1/P2 | terminated | 17 | Yale University | Jan 2009 | |
| NCT00662311 | Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients Unable to Tolerate Cisplatin With Stage III Non-Small Lung Cancer That Cannot Be Removed By Surgery | P1/P2 | terminated | 5 | University of Washington | Mar 2008 | |
| NCT00771472 | MK-0683 | Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) | P1 | completed | 10 | Merck Sharp & Dohme LLC | Aug 2008 |
| NCT01386398 | Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma | P3 | withdrawn | 0 | European Organisation for Research and Treatment of Cancer - EORTC | — | |
| NCT00937495 | Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma | P2 | completed | 16 | National Cancer Institute (NCI) | Jun 2009 | |
| NCT00816283 | Dasatinib and Vorinostat in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Acute Lymphoblastic Leukemia | P1 | completed | 5 | City of Hope Medical Center | Sep 2008 | |
| NCT00330161 | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer | P2 | completed | 29 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT00111813 | AM1 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | P1 | completed | 34 | Merck Sharp & Dohme LLC | Sep 2005 |
| NCT01353482 | MESO-02 | A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma | P1/P2 | withdrawn | 0 | University College, London | — |
| NCT01132911 | A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas | P1 | completed | 5 | National Cancer Institute (NCI) | May 2010 | |
| NCT01208454 | Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma | P1 | completed | 29 | National Cancer Institute (NCI) | Dec 2010 | |
| NCT00363883 | Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium | P2 | terminated | 14 | National Cancer Institute (NCI) | Jun 2006 | |
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | P2 | completed | 44 | National Cancer Institute (NCI) | Jul 2008 | |
| NCT00831493 | Vorinostat Plus Radiation Therapy in Pancreatic Cancer | P1/P2 | terminated | 3 | M.D. Anderson Cancer Center | May 2009 | |
| NCT00258349 | Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer | P1/P2 | completed | 16 | National Cancer Institute (NCI) | Aug 2006 | |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | P1 | terminated | 30 | City of Hope Medical Center | May 2010 | |
| NCT00589472 | TARGET | Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer | P2 | completed | 19 | National Cancer Institute (NCI) | Nov 2007 |
| NCT00907738 | MK-0683 | A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007) | P2 | completed | 27 | Merck Sharp & Dohme LLC | Aug 2005 |
| NCT01130506 | Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | P1 | completed | 17 | National Cancer Institute (NCI) | May 2010 | |
| NCT00810576 | Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma | P2 | terminated | 1 | M.D. Anderson Cancer Center | Jan 2009 | |
| NCT00423449 | MK0683-058 | Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) | P1 | completed | 61 | Merck Sharp & Dohme LLC | Mar 2007 |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | P2 | completed | 103 | National Cancer Institute (NCI) | Sep 2005 | |
| NCT01076530 | Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors | P1 | completed | 27 | National Cancer Institute (NCI) | Feb 2010 | |
| NCT00278395 | Vorinostat in Treating Patients With Kidney Cancer | P2 | completed | 14 | National Cancer Institute (NCI) | Oct 2005 | |
| NCT00697476 | Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent SCLC | P1/P2 | terminated | 2 | Armando Santoro, MD | Jan 2009 | |
| NCT00667082 | NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma | P1 | completed | 22 | Celgene | Mar 2008 | |
| NCT00305773 | Vorinostat in Treating Patients With Acute Myeloid Leukemia | P2 | completed | 37 | National Cancer Institute (NCI) | Jan 2006 | |
| NCT01039363 | Vorinostat Combined With Gemtuzumab Ozogamicin, Idarubicin and Cytarabine in Acute Myeloid Leukemia | P2 | unknown | 27 | Samsung Medical Center | — | |
| NCT00801151 | Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer | P1 | terminated | 30 | Institut Claudius Regaud | Jan 2009 | |
| NCT00565227 | Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. | P1 | terminated | 12 | University of Michigan Rogel Cancer Center | Apr 2007 | |
| NCT00217412 | Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia | P1 | completed | 60 | National Cancer Institute (NCI) | Aug 2005 | |
| NCT00994500 | Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma | P1 | completed | 20 | National Cancer Institute (NCI) | Aug 2009 | |
| NCT00455351 | PRAVO | Vorinostat and Palliative Radiotherapy | P1 | completed | 15 | Oslo University Hospital | Feb 2007 |
| NCT00127127 | MK-0683-029 | A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029) | P1 | completed | 18 | Merck Sharp & Dohme LLC | Jun 2005 |
| NCT00486720 | SAHA | Phase IIa Vorinostat (MK0683, Suberoylanilide Hydroxamic Acid (SAHA)) Study in Lower Risk Myelodysplastic Syndromes (0683-064) | P2 | terminated | 22 | Merck Sharp & Dohme LLC | Jun 2007 |
| NCT00481078 | Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | P2 | completed | 94 | National Cancer Institute (NCI) | May 2007 | |
| NCT00772798 | A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer | P2 | unknown | 70 | Herlev Hospital | Jun 2007 | |
| NCT00132028 | Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma | P2 | completed | 27 | National Cancer Institute (NCI) | Sep 2005 | |
| NCT00632931 | COMPLETED | A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED) | P1 | completed | 25 | Merck Sharp & Dohme LLC | Jul 2007 |
| NCT00134043 | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | P2 | completed | 19 | National Cancer Institute (NCI) | Dec 2005 | |
| NCT00473889 | NSCLC | A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | P2/P3 | terminated | 253 | Merck Sharp & Dohme LLC | May 2007 |
| NCT00138203 | Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer | P2 | completed | 16 | National Cancer Institute (NCI) | Jun 2005 | |
| NCT00127101 | HDAC | An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients (0683-016)(TERMINATED) | P1 | terminated | 23 | Merck Sharp & Dohme LLC | Sep 2005 |
| NCT00132067 | Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer | P2 | completed | 60 | National Cancer Institute (NCI) | Oct 2005 | |
| NCT00045006 | Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jul 2001 | |
| NCT00673153 | Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | P2 | terminated | 31 | Fred Hutchinson Cancer Center | Mar 2008 | |
| NCT00132002 | Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer | P2 | terminated | 14 | National Cancer Institute (NCI) | Jun 2005 | |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | P1/P2 | completed | 29 | University of Washington | Dec 2007 | |
| NCT00106626 | Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors | P1 | completed | 52 | Merck Sharp & Dohme LLC | Aug 2005 | |
| NCT00373490 | A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) | P1 | completed | 16 | Merck Sharp & Dohme LLC | Jul 2006 | |
| NCT00251589 | A Phase I/II Clinical Trial of Vorinostat in Combination With Erlotinib for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer (0683-025) | P1/P2 | terminated | 23 | Merck Sharp & Dohme LLC | Jan 2006 | |
| NCT00499811 | Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction | P1 | completed | 15 | National Cancer Institute (NCI) | Jun 2007 | |
| NCT00424775 | NSCLC | A Study of Carboplatin + Paclitaxel and MK0683 in Patients With Chemotherapy-naive Non-Small Cell Lung Cancer (NSCLC)(0683-066) | P1 | terminated | 3 | Merck Sharp & Dohme LLC | Jan 2007 |
| NCT00419367 | Compassionate Use of Vorinostat for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma (0683-042) | — | no longer available | 0 | Merck Sharp & Dohme LLC | — | |
| NCT00097929 | An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013) | P2 | completed | 18 | Merck Sharp & Dohme LLC | May 2005 | |
| NCT00357708 | Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases | P1 | completed | 50 | National Cancer Institute (NCI) | Jun 2006 | |
| NCT00357305 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders | P1 | completed | 25 | National Cancer Institute (NCI) | May 2006 | |
| NCT00331955 | Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors | P1 | completed | 40 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT00324480 | Vorinostat and Alvocidib in Treating Patients With Advanced Solid Tumors | P1 | completed | 60 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT00331513 | Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes | P1 | completed | 40 | National Cancer Institute (NCI) | Mar 2006 | |
| NCT00091559 | Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) | P2 | completed | 74 | Merck Sharp & Dohme LLC | Feb 2005 | |
| NCT00109109 | SAHA | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004) | P1 | terminated | 60 | Merck Sharp & Dohme LLC | Dec 2003 |
| NCT00278330 | Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia | P1 | completed | 24 | National Cancer Institute (NCI) | Jan 2006 | |
| NCT00310024 | Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | P1 | completed | 40 | National Cancer Institute (NCI) | Nov 2005 | |
| NCT00243100 | Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | P1 | completed | 21 | National Cancer Institute (NCI) | Nov 2005 | |
| NCT00750178 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008) | P1 | completed | 30 | Merck Sharp & Dohme LLC | Nov 2004 | |
| NCT00126451 | SAHA | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) | P2 | terminated | 16 | Merck Sharp & Dohme LLC | Dec 2004 |
| NCT00121277 | Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors | P1 | completed | 28 | University Health Network, Toronto | Sep 2005 | |
| NCT00287937 | Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors | P1 | completed | 30 | National Cancer Institute (NCI) | Jul 2005 | |
| NCT00227513 | Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors | P1 | completed | 66 | National Cancer Institute (NCI) | Jul 2005 | |
| NCT00138177 | Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors | P1 | completed | 54 | National Cancer Institute (NCI) | Jul 2005 | |
| NCT00005634 | Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy | P1 | completed | 0 | Memorial Sloan Kettering Cancer Center | Jan 2000 |
Vorinostat clinical trials: frequently asked questions
- How many Vorinostat clinical trials are there?
- 272 Vorinostat clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 10 are actively recruiting participants. 159 are marked completed.
- Are Vorinostat clinical trials recruiting in 2026?
- Yes — 10 Vorinostat trials are actively recruiting in 2026, with 41 U.S. sites across 23 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Vorinostat being studied for?
- Vorinostat is being studied for Lymphoma, Multiple Myeloma, Unspecified Adult Solid Tumor, Protocol Specific, Recurrent Adult Acute Myeloid Leukemia, Breast Cancer and 709 more. The trials are grouped by indication on this page.
- What phase is Vorinostat in?
- Vorinostat clinical trials span 6 Phase 3, 86 Phase 2, 108 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Vorinostat clinical trials?
- The lead sponsor across the most Vorinostat trials is National Cancer Institute (NCI), with 102 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Vorinostatas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: